Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis
Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis
复制标题
DOI：
10.1128/aac.00629-19
复制
发表时间：
2019-08-01
影响因子：
4.9
通讯作者：
Cook, Gregory M.
中科院分区：
文献类型：
--
作者：
McNeil, Matthew B.;Cook, Gregory M.
迫切需要新的治疗剂来治疗结核分枝杆菌感染。用于验证新靶标的遗传策略是可用的，但其耗时的性质限制了其效用。在这里，使用MmpL3作为模型靶标，我们报告了分枝杆菌CRISPR干扰用于快速验证靶标重要性和化合物作用模式的应用。这一战略有可能迅速加速结核病药物的发现。
There is an urgent need for novel therapeutics to treat Mycobacterium tuberculosis infections. Genetic strategies for validating novel targets are available, yet their time-consuming nature limits their utility. Here, using MmpL3 as a model target, we report on the application of mycobacterial CRISPR interference for the rapid validation of target essentiality and compound mode of action. This strategy has the potential to rapidly accelerate tuberculosis drug discovery.